Core Viewpoint - Hongyuan Pharmaceutical provided insights into its procurement of production raw materials, emphasizing the importance of various factors in the purchasing process [1] Group 1: Raw Materials - The main raw materials required by the company include ethylene glycol, ethylene oxide, acetaldehyde, nitric acid, ammonia water, lithium fluoride, and methyl cyanoacetate [1] - Most of these materials are basic chemical products, with a large number of companies in the industry and relatively mature processes [1] Group 2: Procurement Considerations - When procuring raw materials, the company considers multiple factors such as price, quality, timeliness of supply, stability, payment terms, and transportation [1] - Detailed information regarding the procurement prices of major raw materials from 2019 to 2021 can be found in the company's prospectus, specifically in Section 6 "Business and Technology" and Chapter 5 "Purchasing Situation of the Issuer" [1]

Core Viewpoint - The company is enhancing its lithium battery segment by integrating electrolyte additives and functional lithium salts with its lithium hexafluorophosphate business, aiming to improve business scale and market competitiveness [1] Group 1 - The company is actively engaging with investors through interactive platforms to provide updates on its strategic initiatives [1] - The focus on electrolyte additives and functional lithium salts indicates a strategic move to diversify and strengthen its product offerings in the lithium battery market [1] - The integration of these products with the existing lithium hexafluorophosphate business is expected to create synergies that will benefit the overall business performance [1]

证券日报网讯宏源药业11月14日在互动平台回答投资者提问时表示，公司产品成本受多种因素影响，具 体营业收入、营业成本、营业利润情况，请关注公司定期报告。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the article highlights that the upgrade rate of stocks with consecutive gains exceeds 50%, indicating strong market interest and activity in certain sectors [1] - A total of 70 stocks hit the daily limit up, with 21 stocks classified as consecutive gainers, including 10 stocks with three or more consecutive gains [1] - The upgrade rate for consecutive gainers is reported at 55.56%, excluding ST and delisted stocks, reflecting a robust performance in the market [1] Group 2 - The article notes that local stocks related to map speculation are performing well, with Pingtan Development achieving 13 consecutive gains in 21 days, Sanmu Group with 7 gains in 10 days, and Dongbai Group with 6 gains in 8 days [1] - Defensive sectors such as coal, gas, and electricity have seen a rise due to cold weather news, with Antai Group achieving 13 gains in 22 days and Daya Energy with 2 gains in 4 days [1] - The lithium battery sector experienced a split after a previous surge, with companies like Furui Shares achieving 7 consecutive gains and Shida Shenghua with 3 consecutive gains, while others like Aoke Shares and Tianhong Lithium fell over 9% [1]

Core Viewpoint - Hongyuan Pharmaceutical (301246.SZ) is currently experiencing a significant decline in stock price, closing at 20.82 yuan with a drop of 7.05%, indicating a state of being below the initial offering price [1]. Group 1: Stock Performance - On its first day of trading, Hongyuan Pharmaceutical reached a peak stock price of 45 yuan, but has since experienced a downward trend [2]. - The stock was listed on March 20, 2023, and has been in a state of decline since its initial high [1][2]. Group 2: Fundraising and Financials - The total amount raised from the initial public offering (IPO) was 236.286 million yuan, with a net amount of 219.584 million yuan after deducting issuance costs [2]. - The net fundraising amount exceeded the original plan by 154.511 million yuan, indicating strong investor interest [2]. - The company initially planned to raise 65.073 million yuan for various projects, including a research center and high-end formulation production [2]. Group 3: Issuance Costs - The total issuance costs for the IPO amounted to 16.701 million yuan, with underwriting and sponsorship fees accounting for 13.932 million yuan [3].

Core Viewpoint - Hongyuan Pharmaceutical (301246.SZ) is strategically expanding its product offerings to include electrolyte additives and functional lithium salts, which will synergize with its lithium hexafluorophosphate business, thereby enhancing the scale and market competitiveness of its lithium battery segment [1]. Group 1 - The company is focusing on the development of electrolyte additives and functional lithium salts [1]. - This expansion is aimed at creating industrial synergy with its existing lithium hexafluorophosphate business [1]. - The initiative is expected to continuously improve the business scale and market competitiveness of the company's lithium battery sector [1].

（编辑 王雪儿） 证券日报网讯 宏源药业11月13日在互动平台回答投资者提问时表示，公司六氟磷酸锂是电解液的主要 材料，下游客户是电解液厂家。公司高度重视客户关系维护，并注重保护客户隐私，具体情况请关注公 司的信息披露。 ...

证券日报网讯宏源药业（301246）11月12日在互动平台回答投资者提问时表示，公司生产和研发的产品 具体情况请关注公司的相关信息披露。 ...

Core Viewpoint - The company, Hongyuan Pharmaceutical, emphasizes its commitment to focusing on its core business and enhancing company value for long-term stable development [1] Group 1 - The company will continue to concentrate on its main operations [1] - The company aims to actively enhance its value [1] - The company encourages stakeholders to pay attention to relevant information disclosures regarding project progress and R&D specifics [1]

Core Viewpoint - Hongyuan Pharmaceutical confirmed that the production and sales of lithium hexafluorophosphate are operating normally, with full production and sales capacity [2] Company Summary - Hongyuan Pharmaceutical is currently producing and selling lithium hexafluorophosphate at full capacity [2]